The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Netwo
About this program
The Experimental Therapeutics Clinical Trials Network (ETCTN) is designed to facilitate the development of new therapeutic strategies for cancer treatment through clinical trials. This grant specifically supports lead academic organizations that will play a pivotal role in conducting these trials, ensuring that innovative therapies are tested and evaluated effectively. The ETCTN aims to enhance collaboration among researchers, institutions, and industry partners to accelerate the translation of laboratory discoveries into clinical applications. Eligible organizations will be responsible for coordinating clinical trial activities, managing data, and ensuring compliance with regulatory requirements. This initiative is crucial for advancing cancer research and improving patient outcomes by bringing new treatments to the forefront of clinical practice. The grant is intended for institutions with a strong track record in clinical research and a commitment to advancing cancer therapeutics.
Eligibility
Lead academic organizations with experience in clinical trials and cancer research.